FT
ALNY icon

Fiduciary Trust’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fiduciary Trust’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$226K Buy
683
+3
+0.4% +$1.02K ﹤0.01% 813
2025
Q4 		$270K Buy
680
+7
+1% +$3.1K ﹤0.01% 750
2025
Q3 		$307K Hold
673
– – ﹤0.01% 700
2025
Q2 		$219K Buy
+673
New +$186K ﹤0.01% 781

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fiduciary Trust's ALNY Position: Q1 2026 in Review

Fiduciary Trust increased its Alnylam Pharmaceuticals (ALNY) stake by 0.44% in Q1 2026, buying an estimated $1.02K and bringing the position to 683 shares worth $226K. The position accounts for ﹤0.01% of the portfolio, ranked #813.

Fiduciary Trust first reported a position in ALNY in Q2 2025 and has held it in 4 quarters since. The position peaked at $307K in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Fiduciary Trust held 683 shares of Alnylam Pharmaceuticals worth $226K as of Q1 2026.
  • Fiduciary Trust bought 3 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.02K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Fiduciary Trust's portfolio in Q1 2026, its #813 holding.
  • Fiduciary Trust first reported a position in Alnylam Pharmaceuticals in Q2 2025 and has held it in 4 quarters since.
  • Fiduciary Trust's Alnylam Pharmaceuticals position peaked at $307K in Q3 2025.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Fiduciary Trust's 13F filing for Q1 2026, filed 15 May 2026.